Abstracts tagged "Diabetes"

Abstract Number: 839 • 2019 ACR/ARP Annual Meeting
Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis
Joshua Baker¹, Bryant England ², Michael George ³, Grant Cannon ⁴ and Ted Mikuls ⁵, ¹University of Pennsylvania, Philadelphia, PA, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ³University of Pennsylvania, Philadelphia, ⁴Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis is associated with a higher risk of diabetes mellitus (DM) and cardiovascular disease. While disproportional obesity and visceral fat accumulation may contribute…
Abstract Number: 1409 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Use of abatacept, a targeted DMARD (tDMARD), in patients with RA has shown to improve whole-body insulin sensitivity and reduce HbA1c levels.1 Comparative evidence…
Abstract Number: 1977 • 2019 ACR/ARP Annual Meeting
The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment
Carlos Vaamonde-García¹, Tamara Hermida-Gómez ², Francisco J. Blanco ³, Elena F Burguera ³ and Rosa Meijide-Faílde ¹, ¹Tissue Engineering and Regenerative Medicine Group. University of A Coruña, A Coruña, Spain, ²Unidad de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). Grupo de Investigación en Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Centro de Investigaciones Científicas Avanzadas (CICA), A Coruña, Spain, ³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: A growing number of findings indicates that type 2 diabetes is an independent risk factor of osteoarthritis (OA). However, the mechanisms underlying the connection…
Abstract Number: 2366 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA experienced an increase in the whole-body insulin sensitivity and a reduction in HbA1c levels from treatment with abatacept, which is a…
Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Ana Goico ¹, Anoka Martis¹, Chistopher Kabir ¹, David Mael ¹ and Shoeb Mohammed ¹, ¹Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…
Abstract Number: 223 • 2018 ACR/ARHP Annual Meeting
The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry
Huifeng Yun¹, Fenglong Xie¹, Lang Chen¹, Shuo Yang¹, Leticia Ferri², Evo Alemao², Tammy Curtice² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The impact of concomitant comorbidities on RA outcomes is of high interest, and some evidence suggests that patients (pts) with RA and diabetes may…
Abstract Number: 503 • 2018 ACR/ARHP Annual Meeting
Waist Circumference Based Abdominal Obesity Versus Body Mass Index in Rheumatoid Arthritis: Influence on the Risk of Diabetes and Cardiovascular Disease
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud^1,2, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Adipose tissue deposited around the mesentery is highly associated with insulin resistance and cardiovascular disease (CVD). Compared to BMI, waist circumference (WC) has been…
Abstract Number: 1276 • 2018 ACR/ARHP Annual Meeting
Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population
Anastasia Slobodnick¹, Virginia Pike², Michael Toprover¹ and Michael Pillinger¹, ¹Medicine/Rheumatology, NYU School of Medicine, New York, NY, ²Medicine/Rheumatology, New York Harbor VA Healthcare System, New York, NY
Background/Purpose: Previous studies suggest that patients with gout are at increased risk for developing diabetes.1 One possible explanation for this increased risk is the activation…
Abstract Number: 1534 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Diabetes Mellitus in Rheumatoid Arthritis Patients Treated with Different Biologics- a Cohort Study
Rishi J. Desai¹, Sara Dejene², Yinzhu Jin², Jun Liu³ and Seoyoung C. Kim², ¹Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) often develop diabetes mellitus (DM), potentially due to aggravated systemic inflammation. Reducing inflammation with disease-modifying antirheumatic drugs (DMARD) may…
Abstract Number: 1548 • 2018 ACR/ARHP Annual Meeting
Favorable Effect of Hydroxychloroquine in Patients with Rheumatoid Arthritis and Diabetes or Impaired Glucose Control
Farhana Polara, Mohmed Imran Gora and Shante Hinson, Internal Medicine, Lincoln Medical and Mental hospital, Bronx, NY
Background/Purpose: Hydroxychloroquine (HCQ) is widely prescribed for patients with Rheumatoid Arthritis (RA) and Systemic Lupus Erythromatus (SLE). It is fairly well tolerated with multiple well…
Abstract Number: 1550 • 2018 ACR/ARHP Annual Meeting
Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Christof Specker¹, Annette Alberding², Martin Aringer³, Gerd R. Burmester⁴, Jan-Paul Flacke⁵, Michael Hofmann⁶, Peter Kaestner⁷, Herbert Kellner⁸, Frank Moosig⁹, Maren Sieburg¹⁰, Hans-Peter Tony¹¹ and Gerhard Fliedner¹², ¹Rheumatology and Clinical Immunology, Universitätsklinikum Essen, Essen, Germany, ²Internal Rheumatology, Krankenhaus St. Josef, Wuppertal, Germany, ³Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁶Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ⁷Rheumatology, Ambulantes Rheumazentrum, Erfurt, Germany, ⁸Ambulantes Rheumazentrum, Erfurt, Germany, ⁹Rheumatology Center Schleswig-Holstein Mitte, Neumuenster, Germany, ¹⁰Rheumatologische Gemeinschaftspraxis, Magdeburg, Germany, ¹¹Rheumatology/Immunology, Medizinische Klinik II, Universitätsklinik, Würzburg, Germany, ¹²Rheumatological Practice, Osnabrueck, Germany
Background/Purpose: Interleukin 6 (IL-6) and C-reactive protein (CRP) are independent risk factors for type 2 diabetes mellitus [1], and IL-6 plays a role in insulin…
Abstract Number: 1880 • 2018 ACR/ARHP Annual Meeting
Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
Avneek Singh Sandhu¹, Reto Kurmann², Cynthia S. Crowson³, Rekha Mankad², Eric L. Matteson⁴, Thomas Osborn¹, Kenneth J. Warrington⁵ and Ashima Makol¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Cardiac involvement, due to impairment of coronary microcirculation and myocardial fibrosis, affects prognosis in individuals with SSc, and represents one of the leading causes…
Abstract Number: 1957 • 2018 ACR/ARHP Annual Meeting
Peri-Operative Glycemic Evaluation Prior to Total Joint Replacement in Patients with and without Diabetes
Lindsey A. MacFarlane¹, Yinzhu Jin², Patricia D. Franklin³, Joyce Lii⁴, Jeffrey N. Katz⁵ and Seoyoung C. Kim⁶, ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worchester, MA, ⁴Brigham and Women'a Hospital, Boston, MA, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Elevated hemoglobin A1c (HbA1c) has been associated with a 9-fold increase in wound complications after total joint replacement (TJR). Data suggest that including HbA1c…
Abstract Number: 2587 • 2018 ACR/ARHP Annual Meeting
The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
Santhi Mantravadi¹, Michael D. George² and Alexis Ogdie³, ¹Department of Clinical Pharmacology, Division of Rheumatology, Jefferson University School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Tumor necrosis factor (TNF) is a key inflammatory cytokine in the pathogenesis of psoriatic arthritis (PsA), RA, ankylosing spondylitis (AS), and diabetes mellitus (DM). …
Abstract Number: PP02 • 2018 ACR/ARHP Annual Meeting
Sustained Weight Loss Managed by Multiple Medical Specialists
Lawrence Phillips, Arthritis Foundation, Atlanta, GA
Background/Diagnosis: A patient who was diagnosed in 1974 with type 1 diabetes and in 2000 with rheumatoid arthritis weighed 366 pounds in 2014. He found…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].